Core Viewpoint - The article highlights the significant increase in IPO applications on the Sci-Tech Innovation Board, with 48 companies accepted in 2025 compared to only 6 in 2024, particularly emphasizing the semiconductor sector with 20 companies [1]. Group 1: Company Summaries - Angrui Micro, based in Beijing, focuses on RF and analog integrated circuit design and has successfully completed its IPO process, emphasizing domestic substitution in RF and analog chips [1]. - Shanghai Super Silicon specializes in the R&D and production of 300mm and 200mm semiconductor silicon wafers, which are critical substrates for chip manufacturing [1]. - Hengyun Chang, located in Shenzhen, develops plasma RF power systems and devices, essential for advanced chip manufacturing processes [1]. - Chipmi Technology, based in Shanghai, focuses on semiconductor-grade perfluoroether rubber materials, crucial for sealing in semiconductor production [1]. - Zhaoxin Integrated, also in Shanghai, develops high-end general-purpose processors and supporting chips, aiding in domestic chip substitution [2]. - Shanghai Superconductor specializes in high-temperature superconducting materials, enhancing semiconductor device performance [2]. - Youxun Co., based in Xiamen, is a leader in optical communication front-end transceiver chips, recognized as a national champion in manufacturing [2]. - Yadian Technology, located in Jiangsu, develops wet cleaning equipment for silicon-based and compound semiconductors, vital for chip manufacturing precision [3]. - Moer Thread, based in Beijing, focuses on GPU and related products, aligning with high-end industry development needs [3]. - Muxi Co., located in Shanghai, specializes in full-stack GPU products, supporting AI training and general computing [3]. - Qinheng Micro, based in Nanjing, develops interface chips and interconnect MCUs, essential for embedded systems [4]. - Youyan Composite Materials, located in Beijing, produces special non-ferrous metal alloy products for semiconductor packaging [4]. - Lianxun Instruments, based in Suzhou, develops electronic measurement instruments and semiconductor testing equipment [4]. - Lepu Technology, based in Chengdu, focuses on high-end semiconductor equipment, crucial for chip manufacturing [4]. - Zhongke Kehua, located in Jiangsu, specializes in semiconductor packaging materials, impacting chip packaging quality [5]. - Pinzhun Laser, based in Shanghai, develops precision lasers for semiconductor production processes [5]. - Changxin Technology, located in Anhui, focuses on DRAM products, contributing to domestic storage chip production [5]. - Ruishi Chuangxin, based in Chongqing, develops RF front-end chips and modules for various applications [5]. - Taosheng Technology, based in Shanghai, specializes in semiconductor testing interfaces, crucial for product quality assurance [6]. - Zhongtu Technology, located in Dongguan, develops GaN substrates, essential for high-end chips and new energy applications [6]. Group 2: Market Trends and Characteristics - The 20 companies show a significant regional concentration in Shanghai, Jiangsu, Beijing, and Guangdong, indicating a well-developed semiconductor industry ecosystem in these areas [12]. - The companies cover a comprehensive industry chain, including upstream materials, midstream chip design, and downstream testing and packaging, aligning with collaborative industry development trends [12]. - There is a notable profit disparity among the companies, with many in the high R&D investment sectors like chip design operating at a loss, while those in testing and materials are achieving profitability [12].

Core Insights - North Chip Life Technology Co., Ltd. has officially listed on the STAR Market, marking the first medical IPO of the year and achieving a market capitalization exceeding 20 billion yuan shortly after its debut [1][2] - The company was founded by Dr. Song Liang, who identified a critical technology gap in cardiovascular precision diagnosis and has since developed innovative medical devices [1][3] - North Chip Life is the first domestic high-end medical device company to successfully list on the STAR Market since the resumption of the fifth set of listing standards [1][5] Company Background - Dr. Song Liang, born in 1982, graduated from Wuhan University and later obtained a Ph.D. in biomedical engineering from the University of Washington [2] - After returning to China, he established a research lab at the Shenzhen Institute of Advanced Technology and began focusing on clinical needs in cardiovascular disease treatment [2][3] - The company was founded in 2015 and has developed the first domestic FFR system based on MEMS sensors, addressing a significant market gap [3] Product Development - North Chip Life has developed a total of 17 products in the cardiovascular interventional medical device field, including FFR systems and IVUS systems, with clinical applications in over 1,000 hospitals globally [3][4] - The company achieved a market-leading position with its 60MHz high-definition IVUS product shortly after its approval in China [3] Financial Performance - The company reported revenues of 92.45 million yuan in 2022, with projections of 184 million yuan and 317 million yuan for 2023 and 2024, respectively [4] - North Chip Life turned a profit before its IPO, with a net profit of 49.44 million yuan in the first half of 2025, indicating growing recognition in the global market [4] Investment and Support - The company has attracted significant investment from notable venture capital and private equity firms, including Sequoia China and Qiming Venture Partners, reflecting strong confidence in its growth potential [6][9] - North Chip Life has successfully completed multiple funding rounds, with key investors supporting its strategic vision and product development [8][9] Market Context - The IPO of North Chip Life signals a reopening of the A-share market for medical companies, with several other firms also preparing for listings [11][13] - The recent trend indicates a growing interest in domestic medical innovations, with many companies seeking to capitalize on favorable market conditions [12][14]

红杉中国董事总经理曹弋博（左）与北芯生命创始人、董事长兼CEO宋亮博士在上市仪式 现场。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，深圳北芯生命科技股份有限公司（以下简称"北芯生命"）于2026年2月5日正式 以"688712.SH"为股票代码在上海证券交易所科创板挂牌上市。 值得一提的是， 北芯生命是重启科创板第五套标准后，该标准下第三家、医疗器械行业首家成功上 市企业，也是2024年以来首家在科创板成功上市的医疗器械企业。 作为国内首家拥有血管内功能学血流储备分数（FFR）及影像学血管内超声（IVUS）产品组合的国 产医疗器械公司，北芯生命自成立以来已获得红杉中国等多家知名机构的投资。 其中， 红杉中国于2018年领投了北芯生命的B轮融资且在后续各轮融资中持续支持。IPO前，红杉 中国持有北芯生 命超10%的股份，为公司最大机构投资方，红杉中国董事总经理曹弋博担任北芯生 命董事，也是在北芯生命服务时间最长的投资人董事 曹弋博表示："北芯生命是红杉中国深耕心血管精准诊疗赛道的重要战略布局。我们认为，真正的国 产替代不应止步于复制，而在于超越 ...

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking it as the first medical device company to do so in 2024 and the first under the new fifth set of standards for the board [2][12]. Company Overview - Established in 2015, Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to transform clinical practices [6][10]. - The company has launched 11 products and has 6 more in development, covering various categories including IVUS systems and FFR systems [6]. Product Highlights - The core product, the IVUS system, is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, featuring high definition, speed, and intelligence [7]. - The FFR system is recognized as the gold standard for PCI treatment guidance and has received high-level recommendations in multiple domestic and international guidelines [7]. - Beixin Life's PFA system is the first in China to be included in breakthrough clinical research at the European Society of Cardiology [8]. Market Impact - The successful launch of Beixin Life's products has filled a significant gap in the domestic market, previously reliant on imported products for precise cardiovascular diagnosis [7][10]. - The company has established a presence in over 30 provinces in China and has clinical applications in more than 1,000 hospitals globally, including in Belgium, Germany, and Italy [8]. Innovation and R&D - Beixin Life emphasizes long-term independent research and technological innovation, having developed four core technology platforms for medical devices [10]. - The company holds 185 domestic and international patents, including 86 invention patents and 14 PCT international patent applications [10]. Future Prospects - The listing is seen as a new starting point for Beixin Life, enabling it to accelerate development in innovation, global market expansion, and capital collaboration [12]. - The cardiovascular intervention field is expected to see significant growth, driven by increasing clinical needs and technological advancements [11]. Investment and Support - Major institutional investors include Sequoia China and Qiming Venture Partners, who have expressed confidence in Beixin Life's innovative capabilities and market potential [14][15]. - The company has received continuous support from its investors, focusing on building a strong product portfolio and enhancing its competitive edge in the market [15][17].

Core Viewpoint - North Chip Life Technology Co., Ltd. successfully listed on the Sci-Tech Innovation Board, marking a significant milestone for the company and the medical device industry in China, with strong investor interest reflected in a subscription multiple of 4595.20 times during the IPO process [1][7]. Company Overview - North Chip Life is the first medical device company to successfully list under the fifth set of standards of the Sci-Tech Innovation Board, emphasizing support for innovative high-end manufacturing enterprises with original technology [1][2]. - The company is recognized for its core products, the intravascular ultrasound (IVUS) diagnostic system and the fractional flow reserve (FFR) measurement system, which are the first domestically approved products in China [3][4]. Market Potential - The market for PCI (Percutaneous Coronary Intervention) procedures in China has surpassed one million annually, yet the penetration rate of IVUS and FFR products remains low, indicating significant growth potential [4][9]. - The company’s FFR system captured 30.6% of the domestic market share in its first year, while the IVUS system has reached approximately 1,000 hospitals since its launch in 2022 [4][5]. Financial Projections - North Chip Life projects revenue for 2025 to be between 520 million to 560 million yuan, representing a year-on-year increase of 64.24% to 76.88%, with net profit expected to reach 78 million to 88 million yuan, indicating a nearly threefold growth [1][10]. R&D and Innovation - The company has invested 389 million yuan in R&D from 2022 to 2024, with R&D expenses projected to account for 35.65% of revenue in 2024 [5][6]. - North Chip Life holds 185 domestic and international patents, with a strong focus on developing a comprehensive product line that includes 17 products across five categories [6]. Recognition and Achievements - The company has received multiple accolades, including recognition as a national "little giant" enterprise and awards for its innovative medical devices, further establishing its credibility in the market [6].

Real Estate - The top 10 real estate companies experienced a year-on-year sales decline of 12% in January, while the top 100 companies saw a decline of 25%, indicating a significant disparity in sales performance among different tiers of companies [5] - Notable performers in terms of sales growth include China Overseas Land & Investment, which saw a 20.5% increase, and China Jinmao, with a 13.3% increase [5] - The government is taking measures to stabilize the real estate market, including direct purchases of second-hand homes to promote sales and inventory reduction, which is expected to improve market sentiment [5] Steel - The price difference between hot-rolled steel and rebar is at a five-year low, indicating a potential shift in market dynamics [5] - The SPDR Gold ETF holdings are at their highest level since June 2022, reflecting increased liquidity in the market [5] - The national PMI new orders index for January stands at 49.20, suggesting a contraction in manufacturing activity [5] Non-ferrous Metals - The price of crude indium has increased by 35% over the past week, indicating strong demand in the consumer electronics sector [6] - Prices for other materials such as lithium hydroxide and polysilicon have decreased, while uranium prices have risen, reflecting mixed trends in the new energy and nuclear sectors [6] Display Technology - Hisense Visual Technology is positioned as a leading global provider of display solutions, focusing on a multi-scenario large display strategy and a comprehensive layout in LCD, laser display, and LED technologies [7] - The company achieved a total revenue of 58.5 billion yuan and a net profit of 2.2 billion yuan in 2024, showcasing its strong market presence [7] Industrial X-ray Detection - Dayun Technology is recognized as a leader in the industrial X-ray detection equipment sector, benefiting from high demand in semiconductor, electronic manufacturing, and new energy battery sectors [8] - The company is expected to enhance its competitive advantage through self-research in core components and product structure upgrades [8] Baidu Group - Baidu's advertising business is under pressure, with a projected year-on-year revenue decline of approximately 8.7% for Q4 2025, primarily due to weak demand for traditional search advertising [9] - The company’s cloud business is experiencing a short-term slowdown, but the reduction in depreciation pressure from previous asset impairments is expected to support non-GAAP operating profit [9] XPeng Motors - XPeng Motors reported a significant decline in January deliveries, down 34.1% year-on-year and 46.6% month-on-month, attributed to the phasing out of subsidies and transitions between old and new products [8]

Company - Dayun Technology is a leading domestic supplier of industrial X-ray intelligent detection equipment and core components, recognized as a national-level "specialized and innovative" small giant [4] - From 2019 to 2024, the company's revenue is expected to grow at a CAGR of approximately 38%, while net profit attributable to the parent company is projected to grow at a CAGR of about 77% [4] - The company has established an integrated product line of "detection equipment + AI software + radiation source," with over a hundred standardized devices [6] - In the field of integrated circuits and electronics manufacturing, the company has covered leading PCB/PCBA customers, ranking among the top in the domestic market share [6] - In the new energy battery sector, the company's equipment covers online and offline detection for power, energy storage, and consumer batteries, and has been applied in new process scenarios such as semi-solid and solid-state [6] - The company has achieved full-chain independent control and large-scale production of radiation sources, with 94.3% of self-developed radiation sources applied in electronic circuit detection equipment in the first half of 2025 [6] - The company has pursued horizontal expansion and vertical deepening through acquisitions, completing investments in companies like Innovation Electronics and Zhuhai Jiuyuan in 2025, which is expected to contribute to sustained revenue growth and profit [6] Industry - The global industrial X-ray detection equipment market is expected to grow at a CAGR of approximately 9.9% from 2025 to 2030, while the Chinese market is projected to grow at a CAGR of about 10.3% [5] - By 2030, the global market size in this field is expected to exceed 100 billion yuan, with the Chinese market expected to surpass 30 billion yuan [5] - In 2024, the market size for X-ray detection equipment in China's semiconductor and electronics manufacturing sector is projected to be 3.98 billion yuan, with an expected CAGR of 13% from 2025 to 2030 [7] - The market size for X-ray detection equipment in China's new energy battery sector is expected to reach 1.3 billion yuan in 2024, with an anticipated CAGR of 10% from 2025 to 2030 [7] - The market size for X-ray detection equipment in China's casting and welding sector is projected to reach 3.74 billion yuan in 2024, with an expected CAGR of 11% from 2025 to 2030, potentially reaching 7.18 billion yuan by 2030 [8]

Core Insights - The article highlights the emergence of Chinese high-end medical equipment manufacturers, particularly United Imaging, as key players in the global market, showcasing their advanced technologies and products [1][2]. Group 1: Company Overview - United Imaging has developed several world-first medical devices, including a 2-meter PET-CT and a 5.0T full-body MRI, demonstrating its growth and the evolution of China's high-end medical equipment industry [1]. - The company has transitioned from being a mere assembler to a leader in the high-end imaging equipment market, previously dominated by international giants like GE, Philips, and Siemens [1]. Group 2: Technological Innovation - United Imaging's success is attributed to its commitment to mastering core technologies, guided by its principle of "three musts": comprehensive coverage, independent research and development, and alignment with international standards [2]. - The company has established over 40 regional headquarters and subsidiaries globally, focusing on localizing its research, production, and marketing efforts to enhance its global presence [2]. Group 3: Industry Impact - Under China's "14th Five-Year Plan," United Imaging is positioned as a leading enterprise that will drive significant growth in the medical device sector, emphasizing the integration of innovation across various chains [3]. - The company's journey from a startup in Shanghai to a global leader exemplifies the importance of independent innovation and the necessity of holding core technologies within the company [3].

摩尔线程、沐曦股份之外，壁仞科技、天数智芯、燧原科技也争相叩开资本市场的大门。寒武纪等一众 企业披露业绩的同时，百度的昆仑芯、阿里的平头哥接连走到台前。 "小作文"可以呼应投资者高预期下的焦虑，但不能成为股价大跌的唯一由头。 从投资者的视角看，无论是寒武纪，还是紧随其后上市的摩尔线程、沐曦股份，大家都面临着背负高预 期之后，如何兑现、何时兑现的考题。硬件的稳定性、性价比、供应能力都是市场的重要考察因素。 附在股价上的预期，自然比单纯的数字更复杂。营收增长幅度、亏损收窄情况、盈利预期的变化，都可 能变成"小作文"制造焦虑的诱导因素。在这个过程中，稍有风吹草动，让市场产生不安情绪自然在所难 免。 从行业自身的视角看，寒武纪需要正视的不仅是资本市场对于芯片题材祛魅，还有同行竞争加剧、同业 态百花齐放。 寒武纪从最初的"高处不胜寒"，到数家国产芯片企业先后奔赴资本市场，股市上相关概念股的稀缺时代 也将结束。 刚刚交出亮眼的业绩，寒武纪就迎来了猝不及防的大跌。 2月4日，寒武纪股价收跌5.32%，报1068元/股，总市值4504亿元。此前一天，公司股价跌去12.88%，市 值从约5300亿元回落到4563亿元，几乎半天 ...

刚刚交出亮眼的业绩，寒武纪就迎来了猝不及防的大跌。 2月4日，寒武纪股价收跌5.32%，报1068元/股，总市值4504亿元。此前一天，公司股价跌去12.88%，市 值从约5300亿元回落到4563亿元，几乎半天蒸发了超过700亿元。 表面看，导火索是一篇流传不广的"小作文"，公司小范围交流中给出的2026年营收指引仅为200亿元， 远低于市场预期。寒武纪很快辟谣，但难挡股市大跌。 自上市起，高估值的寒武纪一直背负着高预期。这种高预期既有国产替代浪潮的大势之趋，也有AI时 代对于芯片需求的蒸蒸日上。 预期之下，以寒武纪为代表，大量国产芯片企业脱颖而出，成为资本市场耀眼的明星。它们普遍估值 高、上市快、融资规模大，在资本市场起起伏伏，关注度也极高。 "小作文"可以呼应投资者高预期下的焦虑，但不能成为股价大跌的唯一由头。 从投资者的视角看，无论是寒武纪，还是紧随其后上市的摩尔线程、沐曦股份，大家都面临着背负高预 期之后，如何兑现、何时兑现的考题。硬件的稳定性、性价比、供应能力都是市场的重要考察因素。 附在股价上的预期，自然比单纯的数字更复杂。营收增长幅度、亏损收窄情况、盈利预期的变化，都可 能变成"小作文"制造焦 ...